small molecule

AYVAKIT

AVAPRITINIB

Loss of exclusivityMarch 2042latest FDA-listed patent expiry

CompanyBlueprint Medicines →See this company's full patent-cliff portfolio

Drug detail

Brand name	AYVAKIT
Active ingredient	AVAPRITINIB
Strength	200MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	January 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
12060354	March 2042	use U-2726
11999744	April 2040	use U-3168
11964980	April 2040	substance, product
9994575	October 2034	substance, product
9200002	October 2034	substance, product
9944651	October 2034	substance, product

Regulatory exclusivity

Code	Expires
ODE-434	May 2030
ODE-356	June 2028
ODE-366	January 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Blueprint Medicines